Article first published online: 11 JUL 2011
© 2011 The Author. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society
British Journal of Clinical Pharmacology
Special Issue: Uropharmacology Themed Section
Volume 72, Issue 2, page 365, August 2011
How to Cite
(2011), Erratum. British Journal of Clinical Pharmacology, 72: 365. doi: 10.1111/j.1365-2125.2011.04027.x
- Issue published online: 11 JUL 2011
- Article first published online: 11 JUL 2011
Vol. 71, Issue 5, 639–641, Article first published online: 11 APR 2011
Dubois EA, Rissmann R & Cohen AF. Rilonacept and canakinumab. Br J Clin Pharmacol 2011; 71: 639–41.
In  there was an error in the drawing of rilonacept molecule (Figure 2). This protein was depicted as heterodimeric antibody but it should show a homodimer consisting of the in-line, fused extracellular domains of IL-1RAcP and the mature extracellular domains of IL-1R1 and the Fc portion of human IgG1 .
The first sentence of the fifth paragraph should have read ‘Rilonacept is a homodimer and consists of the extracellular domains of the IL-1-RAcP and the IL-1-R1 fused to the Fc portion of human IgG1’.
The second sentence of the legend of figure 2 should have read ‘Inset: The antibody rilonacept is composed of a human IgG1 FC domain (white) with the 2 arms specific for IL-1 binding: the extracellular domains of the IL-1 receptor 1 (IL-1-R1 in blue) and of the IL-1 receptor accessory protein (IL-1-RAcP in green) fused in-line on each arm to form a homodimeric antibody.’
We regret the error and apologize for it.